Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

SYRE

Spyre Therapeutics Inc

May 13 • 04:00PM ET

76.31

+1.27 1.69 %

Healthcare • Biotechnology • USA • Mid • NASD

Peers: LKFT ROIV APLS VERA KYMR

| Held by: IWM VTI XBI VXF IBB IWO SCHA VTWO IWN VHT

Index	RUT	P/E	-	EPS (ttm)	-2.36	Insider Own	13.26%	Shs Outstand	78.84M	Perf Week	4.53%
Market Cap	6.63B	Forward P/E	-	EPS next Y	-3.13	Insider Trans	-2.36%	Shs Float	75.33M	Perf Month	19.22%
Enterprise Value	6.04B	PEG	-	EPS next Q	-0.73	Inst Own	84.78%	Short Float	16.22%	Perf Quarter	124.97%
Income	-168.74M	P/S	-	EPS this Y	-46.88%	Inst Trans	23.44%	Short Ratio	11.05	Perf Half Y	244.05%
Sales	0.00M	P/B	11.68	EPS next Y	-7.68%	ROA	-25.30%	Short Interest	12.22M	Perf YTD	132.94%
Book/sh	6.53	P/C	8.94	EPS next 5Y	-22.06%	ROE	-29.26%	52W High	78.80 -3.16%	Perf Year	417.36%
Cash/sh	8.54	P/FCF	-	EPS past 3/5Y	57.01% 44.61%	ROIC	-25.15%	52W Low	13.93 447.81%	Perf 3Y	1893.73%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.42% 5.94%	Perf 5Y	-58.41%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	22.31%	Oper. Margin	-	ATR (14)	4.27	Perf 10Y	-57.43%
Dividend Ex-Date	-	Quick Ratio	8.97	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	67.36	Recom	1.06
Dividend Gr. 3/5Y	- -	Current Ratio	8.97	EPS Q/Q	-46.71%	SMA20	5.65%	Beta	3.11	Target Price	95.20
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	33.65%	Rel Volume	0.70	Prev Close	75.04
Employees	102	LT Debt/Eq	0.00	Earnings	May 05 BMO	SMA200	127.85%	Avg Volume	1.11M	Price	76.31
IPO	Apr 07, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	-11.18% -	Trades		Volume	775,469	Change	1.69%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-14-26	Initiated	Raymond James	Strong Buy	$80
Dec-18-25	Initiated	Mizuho	Outperform	$53
Dec-17-25	Initiated	Citigroup	Buy	$64
Sep-26-25	Initiated	Deutsche Bank	Buy	$43
Apr-08-25	Initiated	Leerink Partners	Outperform	$45
Mar-18-25	Initiated	Wolfe Research	Outperform	$27
Sep-04-24	Initiated	Wedbush	Outperform	$45
Jul-16-24	Initiated	Evercore ISI	Outperform
May-02-24	Initiated	Robert W. Baird	Outperform	$50
Mar-01-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$12 → $35
Dec-20-23	Initiated	BTIG Research	Buy	$32
Dec-11-23	Initiated	Jefferies	Buy	$31
Dec-11-23	Initiated	Guggenheim	Buy	$44
May-04-20	Initiated	Piper Sandler	Overweight	$12
Mar-21-19	Initiated	JP Morgan	Overweight	$14
Sep-04-18	Downgrade	Wells Fargo	Outperform → Market Perform
Apr-24-18	Initiated	Evercore ISI	Outperform	$37
Mar-14-18	Reiterated	Needham	Buy	$8 → $12

Show Previous Ratings

May-05-26 08:08AM	Spyre Therapeutics: Q1 Earnings Snapshot (Associated Press)
08:00AM	Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-01-26 04:28PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire) -6.76%
Apr-16-26 04:15PM	Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million (GlobeNewswire)
Apr-14-26 10:38PM	Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock (GlobeNewswire) +7.78%
04:46PM	Loading…
Apr-13-26 04:46PM	Spyre Therapeutics Announces Proposed Public Offering of its Common Stock (GlobeNewswire) +23.36%
01:12PM	Spyre stock soars as UC drug touts Entyvio-rivalling potential (Clinical Trials Arena)
09:53AM	Spyre Therapeutics Flies On Takeda-Rivaling Ulcerative Colitis Results (Investor's Business Daily)
08:38AM	Spyre drug for inflammatory bowel disease shows promise in early study (BioPharma Dive)
07:00AM	Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients (GlobeNewswire)
Apr-10-26 04:05PM	Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026 (GlobeNewswire)
Apr-03-26 04:01PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Mar-16-26 08:00AM	Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026 (GlobeNewswire) +10.48%
Mar-06-26 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Feb-24-26 04:05PM	Spyre Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
04:17PM	Loading…
Feb-19-26 04:17PM	Spyre Therapeutics: Q4 Earnings Snapshot (Associated Press Finance) +14.28%
04:02PM	Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-18-26 08:00AM	Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach (GlobeNewswire)
Feb-16-26 12:23PM	Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026 (Insider Monkey)
Feb-06-26 04:01PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire) +6.62%
Jan-23-26 04:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire) -6.03%
Jan-15-26 11:35AM	Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating (Insider Monkey)
Jan-12-26 08:00AM	Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 (GlobeNewswire) +7.15%
Jan-08-26 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Dec-08-25 11:30AM	A Short Squeeze Could Send This Little-Known Biotech Stock Soaring (Barchart)
Dec-05-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Dec-01-25 09:46AM	Carvana initiated, Zscaler downgraded: Wall Street's top analyst calls (The Fly)
Nov-17-25 12:15PM	Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003 (Insider Monkey)
Nov-07-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Nov-04-25 04:54PM	Spyre Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
04:01PM	Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody (GlobeNewswire)
Oct-29-25 04:05PM	Spyre Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-24-25 08:00AM	Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 (GlobeNewswire)
Oct-15-25 04:15PM	Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million (GlobeNewswire) +5.67%
Oct-13-25 09:07PM	Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock (GlobeNewswire) +11.02%
04:01PM	Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants (GlobeNewswire)
Oct-05-25 09:00AM	Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 (GlobeNewswire)
Oct-03-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Sep-24-25 08:35PM	Spyre Therapeutics Inc. (SYRE) Enrolls First Patient in Its Patient 2 SKYWAY Trial (Insider Monkey) +6.12% -8.18%
Sep-15-25 08:00AM	Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases (GlobeNewswire) -5.18%
Aug-05-25 04:17PM	Spyre Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) -5.39%
04:02PM	Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-01-25 04:41PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Jul-03-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Jun-17-25 07:30AM	Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts (PR Newswire) -11.64%
Jun-16-25 04:05PM	Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025 (PR Newswire)
Jun-06-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
May-30-25 09:55AM	Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know (Zacks)
May-28-25 08:30AM	Spyre Therapeutics to Participate in Upcoming June Investor Conferences (PR Newswire)
May-13-25 09:55AM	How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34% (Zacks)
May-08-25 04:05PM	Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire) +9.64%
May-05-25 08:00AM	Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 (PR Newswire) -6.75%
May-02-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Apr-04-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -8.58%
Mar-27-25 04:05PM	Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody (PR Newswire)
Mar-07-25 04:40PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Feb-27-25 04:05PM	Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (PR Newswire) +7.24%
Feb-25-25 08:00AM	Spyre Therapeutics to Participate in Upcoming March Investor Conferences (PR Newswire)
Feb-19-25 08:00AM	Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation (PR Newswire)
Feb-07-25 05:13PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -5.07%
Jan-13-25 08:00AM	Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts (PR Newswire)
Jan-03-25 05:20PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Dec-18-24 08:00AM	Spyre Therapeutics Added to the Nasdaq Biotechnology Index (PR Newswire) -8.31%
Dec-02-24 05:03PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
08:00AM	Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies (PR Newswire)
Nov-25-24 05:11PM	Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference (PR Newswire)
Nov-18-24 09:18PM	Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock (PR Newswire) -6.17%
04:14PM	Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants (PR Newswire)
Nov-12-24 07:30AM	Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-47 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing (PR Newswire) -8.97%
Nov-11-24 04:05PM	Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-47 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024 (PR Newswire)
Nov-07-24 04:05PM	Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire) +5.00%
Nov-01-24 04:44PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Oct-30-24 04:05PM	Spyre Therapeutics to Participate in Upcoming November Investor Conferences (PR Newswire)
Oct-14-24 08:00AM	Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations (PR Newswire) +6.83%
Oct-04-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -5.66%
Oct-01-24 08:00AM	Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer (PR Newswire) -6.63%
Sep-10-24 04:47PM	Spyre Therapeutics to Participate in Upcoming Investor Conference (PR Newswire)
Aug-07-24 11:53PM	SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024 (InvestorPlace) -5.72%
04:05PM	Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire) -5.22%
Jun-18-24 07:30AM	Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-47 Antibody, for the Treatment of Inflammatory Bowel Disease (PR Newswire)
Jun-03-24 05:23PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +5.26% -7.31%
May-29-24 08:30AM	Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference (PR Newswire)
May-15-24 07:30AM	Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors (PR Newswire)
May-09-24 10:54PM	SYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +6.57%
04:02PM	Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-03-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Apr-01-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -7.27%
Mar-18-24 08:00AM	Spyre Therapeutics Announces $180 Million Private Placement (PR Newswire) -11.68%
Mar-04-24 08:50AM	Here's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price Strength (Zacks) +16.96%
Mar-01-24 05:25PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +8.97%
Feb-29-24 04:05PM	Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (PR Newswire) +5.13%
Feb-26-24 07:30AM	Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference (PR Newswire)
Feb-08-24 07:30AM	Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation (PR Newswire)
Feb-06-24 09:55AM	Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fisher (Zacks)
Feb-05-24 07:30AM	Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors (PR Newswire)
Feb-02-24 05:30PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Dec-22-23 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +5.52% +6.22%
Dec-08-23 07:19AM	Spyre Therapeutics raises $180 million to advance anti-inflammatory drugs (BioPharma Dive)

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HENDERSON MICHAEL THOMAS	Director	May 08 '26	Sale	74.40	80,000	5,952,050	88,606	May 08 09:31 PM
MICHAEL HENDERSON	Director	May 08 '26	Proposed Sale	73.10	80,000	5,848,000		May 08 04:22 PM
Burrows Scott L	Chief Financial Officer	May 01 '26	Option Exercise	14.50	12,500	181,250	110,494	May 01 09:35 PM
Burrows Scott L	Chief Financial Officer	May 01 '26	Sale	71.37	12,500	892,125	97,994	May 01 09:35 PM
Sloan Sheldon	Chief Medical Officer	May 01 '26	Option Exercise	27.46	78,333	2,151,024	78,333	May 01 09:34 PM
Sloan Sheldon	Chief Medical Officer	May 01 '26	Sale	71.50	78,333	5,600,701	0	May 01 09:34 PM
Turtle Cameron	Chief Executive Officer	May 01 '26	Sale	71.37	15,000	1,070,507	612,540	May 01 09:34 PM
SHELDON SLOAN	Officer	May 01 '26	Proposed Sale	74.45	78,333	5,831,892		May 01 04:44 PM
SCOTT BURROWS	Officer	May 01 '26	Proposed Sale	74.45	27,500	2,047,375		May 01 04:44 PM
Turtle Cameron	Chief Executive Officer	Apr 01 '26	Sale	49.33	15,000	739,912	627,540	Apr 03 09:30 PM
Sloan Sheldon	Chief Medical Officer	Apr 01 '26	Option Exercise	21.66	7,958	172,370	7,958	Apr 03 09:30 PM
Sloan Sheldon	Chief Medical Officer	Apr 01 '26	Sale	50.00	7,958	397,900	0	Apr 03 09:30 PM
Burrows Scott L	Chief Financial Officer	Apr 01 '26	Option Exercise	14.50	7,500	108,750	105,494	Apr 03 09:29 PM
Burrows Scott L	Chief Financial Officer	Apr 01 '26	Sale	49.34	7,500	370,076	97,994	Apr 03 09:29 PM
SHELDON SLOAN	Officer	Apr 01 '26	Proposed Sale	50.44	7,958	401,402		Apr 01 04:38 PM
Burrows Scott L	Chief Financial Officer	Mar 03 '26	Option Exercise	14.50	2,500	36,250	100,494	Mar 03 09:32 PM
Burrows Scott L	Chief Financial Officer	Mar 03 '26	Sale	40.65	2,500	101,620	97,994	Mar 03 09:32 PM
Turtle Cameron	Chief Executive Officer	Mar 02 '26	Sale	42.19	15,000	632,866	642,540	Mar 03 09:31 PM
SCOTT BURROWS	Officer	Mar 03 '26	Proposed Sale	42.49	10,000	424,900		Mar 03 04:43 PM
CAMERON TURTLE	Director	Mar 02 '26	Proposed Sale	43.01	60,000	2,580,600		Mar 02 04:31 PM
Turtle Cameron	Chief Executive Officer	Feb 02 '26	Sale	32.80	15,000	492,045	657,540	Feb 04 09:33 PM
Turtle Cameron	Chief Executive Officer	Jan 02 '26	Sale	30.68	15,000	460,134	671,907	Jan 06 09:36 PM
Turtle Cameron	Chief Executive Officer	Dec 01 '25	Sale	29.02	15,000	435,356	686,907	Dec 03 09:52 PM
Turtle Cameron	Chief Executive Officer	Nov 03 '25	Sale	23.33	45,000	1,049,778	701,907	Nov 05 09:15 PM
CAMERON TURTLE	Director	Nov 03 '25	Proposed Sale	24.46	90,000	2,201,400		Nov 03 04:24 PM
Burrows Scott L	Chief Financial Officer	Sep 02 '25	Sale	16.26	18,428	299,639	97,994	Sep 03 06:53 PM

Open in Screener

APGE

Apogee Therapeutics Inc

May 13 • 04:00PM ET

83.94

+1.01 1.22 %

Healthcare • Biotechnology • USA • Mid • NASD

APGE Apogee Therapeutics Inc daily Stock Chart

Peers: ARQT ANAB KYMR NRIX IMVT

| Held by: VTI XBI IWM TCAF VXF IWO IBB SCHA VTWO VHT

Index	RUT	P/E	-	EPS (ttm)	-4.33	Insider Own	25.45%	Shs Outstand	61.40M	Perf Week	-0.71%
Market Cap	6.32B	Forward P/E	-	EPS next Y	-5.41	Insider Trans	-9.40%	Shs Float	56.17M	Perf Month	-5.12%
Enterprise Value	5.27B	PEG	-	EPS next Q	-1.09	Inst Own	88.61%	Short Float	16.89%	Perf Quarter	27.55%
Income	-274.62M	P/S	-	EPS this Y	-7.99%	Inst Trans	22.99%	Short Ratio	10.70	Perf Half Y	47.86%
Sales	0.00M	P/B	5.01	EPS next Y	-18.78%	ROA	-27.35%	Short Interest	9.49M	Perf YTD	11.21%
Book/sh	16.77	P/C	5.97	EPS next 5Y	-15.18%	ROE	-28.47%	52W High	95.32 -11.93%	Perf Year	111.22%
Cash/sh	14.07	P/FCF	-	EPS past 3/5Y	-75.11% -	ROIC	-21.78%	52W Low	34.34 144.44%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.42% 4.14%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-22.17%	Oper. Margin	-	ATR (14)	3.68	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	32.59	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	50.69	Recom	1.24
Dividend Gr. 3/5Y	- -	Current Ratio	32.59	EPS Q/Q	-11.87%	SMA20	-2.07%	Beta	0.67	Target Price	118.38
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	3.64%	Rel Volume	0.84	Prev Close	82.93
Employees	261	LT Debt/Eq	0.00	Earnings	May 11 BMO	SMA200	32.02%	Avg Volume	887.25K	Price	83.94
IPO	Jul 14, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.42% -	Trades		Volume	745,803	Change	1.22%

Date	Action	Analyst	Rating Change	Price Target Change
May-01-26	Initiated	Rothschild & Co Redburn	Buy	$140
Mar-18-26	Initiated	Truist	Hold	$83
Jan-22-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$83
Jan-07-26	Initiated	Wolfe Research	Peer Perform
Dec-17-25	Initiated	Stephens	Overweight	$95
Dec-10-25	Initiated	Deutsche Bank	Buy	$103
Nov-03-25	Initiated	Craig Hallum	Buy	$109
Oct-21-25	Initiated	Mizuho	Outperform	$105
Sep-25-25	Initiated	RBC Capital Mkts	Outperform	$60
Jul-07-25	Reiterated	BTIG Research	Buy	$100 → $115
Mar-13-25	Initiated	Citigroup	Buy	$95
Nov-25-24	Initiated	Canaccord Genuity	Buy	$89
May-10-24	Initiated	BofA Securities	Buy	$80
Dec-20-23	Initiated	BTIG Research	Buy	$43
Aug-08-23	Initiated	Wedbush	Outperform	$40
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Stifel	Buy	$34
Aug-08-23	Initiated	Jefferies	Buy	$29
Aug-08-23	Initiated	Guggenheim	Buy	$29

Show Previous Ratings

May-11-26 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results (GlobeNewswire)
Mar-26-26 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million (GlobeNewswire)
Mar-24-26 09:53PM	Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering (GlobeNewswire) -7.87% +7.58%
Mar-23-26 04:01PM	Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering (GlobeNewswire) +19.99%
10:01AM	How Apogee, Up 14%, Plans To Take On Rival Regeneron's Eczema Drug (Investor's Business Daily)
08:15AM	Loading…
08:15AM	Apogee strengthens case for longer-lasting eczema drug (BioPharma Dive)
06:30AM	Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Mar-22-26 07:51PM	Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026 (GlobeNewswire)
Mar-18-26 09:34AM	Block upgraded, Starbucks downgraded: Wall Street's top analyst calls (The Fly)
Mar-10-26 08:04AM	Wedbush Raises Price Target on Apogee Therapeutics (APGE) (Insider Monkey)
Mar-04-26 06:34AM	Apogee Therapeutics Teases 52-Week Zumi Durability Data, Phase III Path at TD Cowen Conference (MarketBeat) +5.56%
Mar-02-26 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results (GlobeNewswire)
Feb-24-26 07:30AM	Apogee Therapeutics to Participate in Upcoming March Conferences (GlobeNewswire)
Feb-18-26 07:39PM	End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations (Insider Monkey)
Feb-16-26 12:23PM	Here is Why Apogee Therapeutics (APGE) Appears Attractive (Insider Monkey)
09:07PM	Loading…
Feb-12-26 09:07PM	Apogee Therapeutics touts quarterly-to-biannual AD dosing shift, expands asthma ambitions at conference (MarketBeat) +5.32%
Feb-05-26 08:00AM	Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-30-26 07:39PM	Elastic NV, Acadia Healthcare, and More Stocks See Action From Activist Investors (Barrons.com) -6.39%
Jan-12-26 12:00PM	Funding for Risky Biotechs Is Returning (The Wall Street Journal)
Jan-07-26 09:41AM	Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly)
Jan-06-26 06:00AM	Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook (GlobeNewswire)
Jan-05-26 04:01PM	Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026 (GlobeNewswire)
Dec-09-25 12:19AM	Strong Pipeline and Analyst Confidence Push Apogee Therapeutics Inc. (APGE) Toward Growth (Insider Monkey)
Nov-11-25 09:40AM	Is Apogee Therapeutics Inc. (APGE) Outperforming Other Medical Stocks This Year? (Zacks) +10.89%
Nov-10-25 07:10AM	Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
07:00AM	Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody (GlobeNewswire)
Nov-03-25 07:30AM	Apogee Therapeutics to Participate in Upcoming Conferences (GlobeNewswire)
Oct-30-25 09:55AM	Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 69.3%: Here's is How to Trade (Zacks)
Oct-17-25 09:55PM	BTIG Maintains a Buy on Apogee Therapeutics (APGE) (Insider Monkey)
Oct-14-25 09:55AM	Does Apogee Therapeutics Inc. (APGE) Have the Potential to Rally 72.52% as Wall Street Analysts Expect? (Zacks)
04:01PM	Loading…
Oct-10-25 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million (GlobeNewswire)
Oct-09-25 05:26PM	Why Apogee Therapeutics Stock Triumphed on Thursday (Motley Fool) +12.64%
01:08PM	Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out (Investor's Business Daily)
Oct-08-25 09:52PM	Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering (GlobeNewswire) +18.90%
04:01PM	Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering (GlobeNewswire)
Sep-30-25 04:00AM	RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating (Insider Monkey)
Sep-15-25 09:09AM	BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis (Insider Monkey)
Sep-11-25 07:30AM	Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress (GlobeNewswire)
Sep-03-25 07:30AM	Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum (GlobeNewswire)
Aug-11-25 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 09:55AM	Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? (Zacks) -5.24%
Jul-31-25 11:38AM	Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug (Insider Monkey)
Jul-16-25 09:38AM	BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating (Insider Monkey)
Jul-14-25 07:52AM	Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE) (Insider Monkey)
Jul-08-25 03:31PM	Regeneron's Blockbuster Dupixent Faces a New Rival (Barrons.com) -7.21%
02:26PM	Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors (Insider Monkey)
Jul-07-25 04:27PM	Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker. (Investor's Business Daily) -17.32%
10:09AM	Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot (Investor's Business Daily)
06:00AM	Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Jul-06-25 06:00PM	Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 (GlobeNewswire)
04:01AM	Apogee Therapeutics Shares Positive Interim Phase 1b Results for APG808 in Asthma (Insider Monkey)
Jun-09-25 09:55AM	Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? (Zacks)
May-29-25 07:30AM	Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-25 09:55AM	Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet (Zacks)
May-12-25 02:21PM	Why Is Apogee Therapeutics Stock Trading Higher On Monday? (Benzinga) +6.14%
06:05AM	Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody, in Patients with Mild-to-Moderate Asthma (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4R Antibody, in Patients with Mild-to-Moderate Asthma (GlobeNewswire)
May-05-25 09:55AM	Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade (Zacks)
May-01-25 08:00AM	Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference (GlobeNewswire)
Apr-14-25 08:04AM	Apogee Therapeutics: Engineering Biologic Dominance (Seeking Alpha)
Mar-26-25 05:50PM	Is Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025? (InsiderMonkey)
Mar-03-25 12:16PM	Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial (Benzinga)
06:05AM	Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990) (GlobeNewswire)
Mar-01-25 09:22AM	Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now? (Insider Monkey)
Feb-28-25 04:00PM	Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025 (GlobeNewswire)
Feb-25-25 07:30AM	Apogee Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-03-25 07:00AM	Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Jan-30-25 03:44PM	Heres Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025 (Insider Monkey) +5.41%
Jan-29-25 07:30AM	Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-10-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions (GlobeNewswire)
Dec-03-24 06:52AM	Apogee Therapeutics Advances in I&I Disease Treatments (TipRanks)
Dec-02-24 06:00AM	Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day (GlobeNewswire)
Nov-29-24 01:00PM	Apogee Therapeutics Announces Agenda for Virtual R&D Day (GlobeNewswire)
Nov-18-24 07:30AM	Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 (GlobeNewswire)
Nov-13-24 07:21AM	Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028 (TipRanks) -7.95%
Nov-12-24 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results (GlobeNewswire) -5.14%
Nov-04-24 07:30AM	Apogee Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-24-24 08:00AM	Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
Oct-16-24 07:00AM	Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting (GlobeNewswire)
Oct-07-24 04:50PM	Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now (Insider Monkey)
Oct-04-24 01:03PM	Wellington Management Group LLP Increases Stake in Apogee Therapeutics Inc (GuruFocus.com)
Sep-12-24 07:00AM	Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit (GlobeNewswire)
Sep-09-24 07:00AM	Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer (GlobeNewswire)
Sep-07-24 01:45AM	Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Aug-24-24 01:30AM	Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Aug-19-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire) +10.59%
Aug-12-24 06:30AM	Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results (GlobeNewswire) +9.78%
Aug-10-24 01:00AM	Apogee Therapeutics Inc (APGE) CEO Michael Henderson Sells 40,000 Shares (GuruFocus.com)
01:00AM	Insider Sale: Carl Dambkowski Sells 7,335 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire)
Jul-06-24 01:00AM	Insider Sale: CEO Michael Henderson Sells 15,000 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
01:00AM	Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
May-28-24 07:30AM	Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD (GlobeNewswire)
May-23-24 07:30AM	Apogee Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-15-24 04:01PM	Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
May-13-24 01:53PM	APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:42AM	Apogee Therapeutics' Q1 Net Loss Widens (MT Newswires)
07:00AM	Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results (GlobeNewswire)

Apogee Therapeutics, Inc. is a clinical stage biotechnology company. It offers treatment of atopic dermatitis (AD), ashma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded by Andrew Gottesdiener and Nimish P. Shah in 2022 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HENDERSON MICHAEL THOMAS	Officer	May 13 '26	Proposed Sale	82.47	60,000	4,948,200		May 13 10:34 AM
Dambkowski Carl	Chief Medical Officer	May 06 '26	Option Exercise	22.86	4,125	94,298	212,523	May 08 08:00 PM
Dambkowski Carl	Chief Medical Officer	May 06 '26	Sale	84.14	5,500	462,784	207,023	May 08 08:00 PM
CARL DAMBKOWSKI	Officer	May 06 '26	Proposed Sale	83.29	22,000	1,832,380		May 06 04:25 PM
Henderson Jane	Chief Financial Officer	May 01 '26	Sale	82.04	2,000	164,080	173,371	May 04 08:00 PM
JANE HENDERSON	Officer	May 01 '26	Proposed Sale	82.89	2,000	165,780		May 01 04:45 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Apr 16 '26	Option Exercise	22.86	3,000	68,580	1,135,987	Apr 20 04:05 PM
Henderson Jane	Chief Financial Officer	Apr 16 '26	Sale	90.00	2,000	180,000	175,371	Apr 17 08:00 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Apr 08 '26	Sale	82.58	20,000	1,651,664	1,132,987	Apr 10 08:00 PM
Dambkowski Carl	Chief Medical Officer	Apr 01 '26	Option Exercise	22.86	4,125	94,298	213,898	Apr 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Apr 01 '26	Sale	84.84	5,500	466,619	208,398	Apr 03 08:00 PM
Henderson Jane	Chief Financial Officer	Apr 01 '26	Sale	85.01	2,000	170,020	177,371	Apr 03 08:00 PM
Henderson Jane	Chief Financial Officer	Mar 25 '26	Sale	85.00	2,000	170,000	179,371	Mar 27 08:00 PM
JANE HENDERSON	Officer	Mar 25 '26	Proposed Sale	73.00	6,000	438,000		Mar 25 04:24 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Mar 11 '26	Sale	74.78	20,000	1,495,605	1,152,987	Mar 13 08:00 PM
Dambkowski Carl	Chief Medical Officer	Mar 04 '26	Option Exercise	22.86	4,125	94,298	215,273	Mar 06 08:00 PM
Dambkowski Carl	Chief Medical Officer	Mar 04 '26	Sale	71.06	5,500	390,825	209,773	Mar 06 08:00 PM
Henderson Jane	Chief Financial Officer	Mar 02 '26	Sale	70.22	2,000	140,431	181,371	Mar 04 08:00 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Feb 11 '26	Sale	63.35	20,000	1,266,953	1,172,987	Feb 13 08:00 PM
HENDERSON MICHAEL THOMAS	Officer	Feb 11 '26	Proposed Sale	64.00	60,000	3,840,000		Feb 11 10:42 AM
Dambkowski Carl	Chief Medical Officer	Feb 04 '26	Option Exercise	22.86	4,125	94,298	216,648	Feb 04 08:02 PM
Dambkowski Carl	Chief Medical Officer	Feb 04 '26	Sale	65.79	5,500	361,860	211,148	Feb 04 08:02 PM
Henderson Jane	Chief Financial Officer	Feb 02 '26	Sale	65.81	2,000	131,630	183,371	Feb 04 08:01 PM
Fairmount Funds Management LLC	Director	Jan 22 '26	Sale	76.30	1,750,000	133,525,000	298,647	Jan 22 08:07 PM
Fairmount Healthcare Fund II L	Director	Jan 22 '26	Proposed Sale	76.30	1,750,000	133,525,000		Jan 22 08:03 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jan 14 '26	Sale	81.11	20,000	1,622,159	1,192,987	Jan 16 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jan 07 '26	Option Exercise	22.86	14,025	320,612	231,223	Jan 09 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jan 07 '26	Sale	77.84	18,700	1,455,613	212,523	Jan 09 08:00 PM
CARL DAMBKOWSKI	Officer	Jan 07 '26	Proposed Sale	78.25	35,200	2,754,400		Jan 07 04:27 PM
Henderson Jane	Chief Financial Officer	Jan 02 '26	Sale	74.86	6,000	449,146	187,371	Jan 06 08:00 PM
Henderson Jane	Chief Financial Officer	Jan 06 '26	Sale	80.00	2,000	160,000	185,371	Jan 06 08:00 PM
JANE HENDERSON	Officer	Jan 02 '26	Proposed Sale	75.48	12,000	905,760		Jan 02 04:31 PM
Henderson Jane	Chief Financial Officer	Dec 19 '25	Sale	80.00	1,500	120,000	193,371	Dec 23 08:00 PM
JANE HENDERSON	Officer	Dec 19 '25	Proposed Sale	77.35	1,500	116,025		Dec 19 04:24 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Dec 10 '25	Sale	75.38	20,000	1,507,657	1,212,987	Dec 12 08:00 PM
Dambkowski Carl	Chief Medical Officer	Dec 04 '25	Sale	75.00	10,900	817,500	271,108	Dec 05 08:03 PM
Henderson Jane	Chief Financial Officer	Dec 04 '25	Sale	75.00	1,500	112,500	194,871	Dec 05 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Dec 04 '25	Sale	75.01	40,000	3,000,400	1,232,987	Dec 05 08:00 PM
JANE HENDERSON	Officer	Dec 04 '25	Proposed Sale	74.55	1,500	111,825		Dec 04 04:43 PM
CARL DAMBKOWSKI	Officer	Dec 04 '25	Proposed Sale	74.55	10,900	812,595		Dec 04 04:41 PM
Henderson Jane	Chief Financial Officer	Nov 25 '25	Sale	70.00	1,500	105,000	196,371	Nov 28 08:00 PM
JANE HENDERSON	Officer	Nov 25 '25	Proposed Sale	67.85	1,500	101,775		Nov 25 04:28 PM
Henderson Jane	Chief Financial Officer	Nov 14 '25	Sale	65.00	2,000	130,000	197,871	Nov 14 08:00 PM
JANE HENDERSON	Officer	Nov 14 '25	Proposed Sale	62.97	2,000	125,940		Nov 14 04:31 PM
Henderson Jane	Chief Financial Officer	Nov 11 '25	Sale	60.00	1,000	60,000	199,871	Nov 13 08:37 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Nov 13 '25	Sale	63.01	20,000	1,260,236	1,272,987	Nov 13 08:24 PM
HENDERSON MICHAEL THOMAS	Officer	Nov 13 '25	Proposed Sale	66.98	100,000	6,697,800		Nov 13 10:33 AM
JANE HENDERSON	Officer	Nov 11 '25	Proposed Sale	56.77	1,000	56,770		Nov 12 07:03 AM
Dambkowski Carl	Chief Medical Officer	Nov 05 '25	Option Exercise	22.86	8,060	184,252	292,793	Nov 07 08:00 PM
Dambkowski Carl	Chief Medical Officer	Nov 05 '25	Sale	55.07	10,785	593,903	282,008	Nov 07 08:00 PM
CARL DAMBKOWSKI	Officer	Nov 05 '25	Proposed Sale	53.90	10,785	581,312		Nov 05 04:17 PM
Dambkowski Carl	Chief Medical Officer	Oct 01 '25	Option Exercise	22.86	2,385	54,521	289,843	Oct 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Oct 01 '25	Sale	39.80	5,110	203,378	284,733	Oct 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Sep 03 '25	Sale	37.87	2,725	103,198	233,548	Sep 05 08:00 PM
Dambkowski Carl	Chief Medical Officer	Aug 06 '25	Sale	37.78	2,725	102,950	236,273	Aug 08 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jul 02 '25	Option Exercise	22.86	7,365	168,364	249,088	Jul 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jul 02 '25	Sale	45.09	10,090	454,954	238,998	Jul 03 08:00 PM
CARL DAMBKOWSKI	Officer	Jul 02 '25	Proposed Sale	44.26	22,345	988,990		Jul 02 04:22 PM
Dambkowski Carl	Chief Medical Officer	Jun 04 '25	Sale	36.96	2,725	100,716	241,723	Jun 06 08:01 PM

SYRE

Spyre Therapeutics Inc

APGE

Apogee Therapeutics Inc

Upgrade your Finviz experience